Christina Schulze

Cologne

Editor at Juve Patent

Reporting on the European patent law market by Christina Schulze, Journalist at https://t.co/u4SVXWSD8A

Featured in: Favicon

juve-patent.com Favicon

mdpi.com

internationaljournalofcardiology.com

Articles

Gucci does not infringe Agfa leather printing patent

1 week ago | juve-patent.com | Christina Schulze

Printing company Agfa sued luxury goods brand Gucci for patent infringement. The case concerns Agfa’s patent EP 3 388 490, which covers a manufacturing method for embellishing natural leather with decorative images. This represents a key future field for Agfa. The company accused Gucci of using this method to decorate leather products, with the patent dispute centring on Gucci’s Pikarar Collection.
South Korean medical device manufacturer Eoflow receives sales ban in UPC territory

1 week ago | juve-patent.com | Christina Schulze

Insulet has filed suits against Eoflow and Menarini over infringement of EP4 201 327, which protects insulin patch pumps. The European patent has unitary effect which can only be asserted before the UPC. Now, the Court of Appeal has ruled Eoflow must cease distribution and advertising of its insulin patch pumps in the UPC territory (case ID: UPC_CoA_768/2024, APL_64374/2024). The plaintiff can enforce the preliminary injunction without providing security.
First French decision on disparagement issue relating to pending UPC cases

2 weeks ago | juve-patent.com | Christina Schulze

From Europe. For the global patent community. JUVE Patent Cases First French decision on disparagement issue relating to pending UPC cases France 2 May 2025 by Christina Schulze On 3 March 2025, Qiagen published a press release announcing it had filed an infringement action against France-based company bioMérieux at the Düsseldorf local division of the UPC (case ID: ACT_9962/2025).
UK High Court revokes AstraZeneca's SPC and patent for diabetes drug dapagliflozin

2 weeks ago | juve-patent.com | Christina Schulze

The UK High Court has found AstraZeneca’s patent EP 1 506 211 invalid (UK [2025] EWHC 1012 (Pat)). Although AstraZeneca will likely appeal the decision, it represents a setback. The manufacturer of the diabetes drug dapagliflozin had recently won a preliminary injunction against Glenmark’s generic version in the UK. As the patent expired two years ago, this decision mainly affects the SPC, which is valid until May 2028.
Ones to Watch UK 2025: Bryce Matthewson

1 month ago | juve-patent.com | Christina Schulze

Every year, JUVE Patent carries out extensive research in the UK patent market, culminating in the publication of the UK patent ranking. Our latest research highlighted Bryce Matthewson, a patent litigator from Powell Gilbert as one of the current ‘Ones to Watch’ in the UK patent market. Can one describe a mechanism in a card shuffling machine, which moves cards up and down, as a carousel? This was one of the first questions that Bryce Matthewson, now 37, tackled in a patent case.
How associate salary structures vary at UK patent practices

1 month ago | juve-patent.com | Christina Schulze

Although data showing City law firm salaries has long been available, making starting salaries for patent litigators in the UK relatively transparent, a persistent misconception exists among lawyers that London salaries are higher than in DÃ¼sseldorf and Munich. Research by JUVE Patent thoroughly refutes this notion. While the top earning potential likely exceeds what is possible in Germany, the research does not support the commonly cited London premium linked to higher living costs.
DAX-listed German bluechips rarely assign board seat to IP

2 months ago | juve-patent.com | Christina Schulze

According to Maria Skottke-Klein, vice president of the German Patent and Trade Mark Office, “Companies with IP rights generate 68% higher revenue per employee and pay on average 19% higher salaries.” Yet in the boardrooms of German DAX companies, IP rights are just one topic among many. Those responsible for IP typically juggle numerous other responsibilities. In addition to corporate strategy and business development, CEOs in particular must handle multiple other areas.
UPC hears first main trial concerning second medical use

2 months ago | juve-patent.com | Christina Schulze

On a bright February morning, around twenty lawyers from each pharmaceutical company filed into the courtroom of the UPC’s DÃ¼sseldorf local division. The atmosphere was tense as presiding judge Ronny Thomas opened the first hearing on the merits concerning second medical use at the UPC (ACT_597355/2023 and CC_24999/2024, UPC_CFI_505/2023).
Federal Court of Justice issues another positive decision for Las Navas Garcia

2 months ago | juve-patent.com | Christina Schulze

In February, the German Federal Court of Justice once again upheld Las Navas Garcia’s EP 1 455 175 (X ZR 137/22). The Spanish company had sued Herzog, a manufacturer of analysis systems, for patent infringement. The dispute concerns analysis furnaces for determining the purity content of mined iron ore. This technology is used, for example, in iron ore mines in Australia, South Africa and China.
UPC to hire multiple new judges in 2025

2 months ago | juve-patent.com | Christina Schulze

The UPC has published its budget for 2025 and it clearly states the number of judges at the UPC will grow significantly this year. Officials will make funds available for 6.9 full-time equivalent judges (FTEs) for the Court of Appeal alone. The budget for the court of first instance will increase from the current 34.6 FTEs to 47.3 FTEs. All additional judgeships are to be achieved in the course of the year both by hiring new judges and by increasing the working hours of existing part-time judges.